FDA premarket approval records identify Seikagaku Corp. as the applicant for Gel-One (P080020) and SUPARTZ FX (P980044), both classified as intra-articular hyaluronic acid devices in class III and reviewed by the Orthopedic advisory committee. The original approvals date to 2011 and 2001 respectively, and both devices carry later supplements. The records place the applicant at a Marunouchi, Chiyoda-ku, Tokyo address, which is a filing address rather than a verified headquarters. [1][2][3][4]
Two approved hyaluronic acid devices
Gel-One was approved under P080020 with a decision date of March 22, 2011, and the approval statement describes an indication for pain in osteoarthritis of the knee in patients who failed to respond adequately to non-pharmacologic therapy, NSAIDs or analgesics such as acetaminophen. SUPARTZ FX was approved under P980044 on January 24, 2001, with an approval statement referencing SUPARTZ(TM) Dispo and an indication for knee osteoarthritis pain after inadequate response to conservative non-pharmacologic therapy and simple analgesics. Both records list the generic name as acid, hyaluronic, intraarticular, product code MOZ, and the Orthopedic advisory committee. [3][4]
The summary of safety and effectiveness data for P080020 names the device as Gel-One, gives the applicant as Seikagaku Corporation at 6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo, and records the FDA approval notice date as March 22, 2011. It states that CDRH issued an approval order that day and that the applicant’s manufacturing facility was inspected and found in compliance with the Quality System regulation at 21 CFR 820. [7]
2026 sterility-testing isolator supplements
Two supplements decided September 4, 2026 address manufacturing process changes. P080020/S056 for Gel-One was received July 7, 2026 under the 135 Review Track for 30-Day Notice, with supplement reason listed as process change affecting manufacturer, sterilizer, packager or supplier. Its approval statement covers replacement of one of two existing isolators used for sterility testing of Gel-One with a new isolator equipped with an integrated hydrogen peroxide decontamination system. [1]
P980044/S067 for SUPARTZ FX was received July 6, 2026 under the same 30-day notice track and the same supplement reason category. Its approval statement describes the same scope of change: replacing one of two existing sterility-testing isolators with a new isolator carrying an integrated hydrogen peroxide decontamination system. Neither record indicates an expanded review; both list the expedited review flag as N. [2]
What the filing record covers
The linked collection contains four premarket approval records, all with an approval decision, split evenly between the two PMA numbers. That count reflects the retrieved filings as of the snapshot date and is not a measure of total portfolio, sales or safety performance. No recall records appear in the retrieved sample. [1][2][3][4]
FDA database pages for P080020 and P080020/S056 note that a device with supplements may have a changed description, function or indication, and direct readers to the supplements for current information. The P980044/S067 page carries the same caution for supplements. Those pages are navigational records; the substantive scope statements sit in the PMA data entries cited above. [5][6][8][9]
Brand documentation and applicant identity
Zimmer Biomet publishes a Gel-One product page describing Gel-One Cross-linked Hyaluronate as a 100% cross-linked gel in a single 3 mL injection, positioned for mild to moderate osteoarthritis of the knee, and directs readers to labeling.zimmerbiomet.com for the current Instructions for Use and full prescribing and risk information. Those product characterizations come from the manufacturer’s page, not from the FDA filings. [10]
The FDA records name Seikagaku Corp. as applicant and do not establish a parent, owner or corporate relationship with any brand publisher. The Zimmer Biomet page is a separate published source about the Gel-One product; it does not identify the applicant’s ownership structure. Corporate relationships beyond the applicant name remain unknown from these documents. [1][2][10]
